Medication info
Omezotans Plus Tablet

Omezotans Plus Tablet

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Donggu Bio Pharmaceutical Co., Ltd.
Appearance
Round film-coated tablet with a reddish-yellow color
Packaging
30 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 201401945 · Approved 2014.04.22 · Insurance code 657306450

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Before administering this medicine, it is recommended that the dose of olmesartan medoxomil or hydrochlorothiazide be adjusted individually. If blood pressure is not adequately controlled with the individual components, administer 1 tablet of this medicine once daily, regardless of meals. Adjust the dose at intervals of 2~4 weeks, taking the patient's blood pressure response into consideration. A marked reduction in blood pressure may occur when olmesartan medoxomil is added to treatment in patients taking high-dose hydrochlorothiazide monotherapy or when such patients are switched to this medicine (olmesartan medoxomil/hydrochlorothiazide), as well as in patients with volume depletion or hyponatremia. In these cases, reduce the hydrochlorothiazide dose to 12.5mg before adding olmesartan medoxomil. <Elderly patients> In elderly patients, start with the lowest dose and use caution when adjusting the dose, taking into consideration the patient's renal or cardiac function, comorbidities, and other concomitant medications. <Patients with renal impairment> This medicine (olmesartan medoxomil/hydrochlorothiazide) is generally administered to patients with mild or moderate renal impairment (creatinine clearance>30mL/min). Do not administer this medicine (olmesartan medoxomil/hydrochlorothiazide) to patients with more severe renal impairment, as loop diuretics are preferable to thiazide diuretics in these patients. <Patients with hepatic impairment> Use of this medicine is not recommended in patients with hepatic impairment because there is no experience with its use in these patients.
Child dose
The safety and efficacy in children have not been established.

Ingredients

Manufacturer
Donggu Bio Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used in patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy with Olmesartan Medoxomil and Hydrochlorothiazide. Essential hypertension occurs without a specific cause, and it is important to lower blood pressure reliably. Olmesartan Medoxomil lowers blood pressure, while Hydrochlorothiazide, as a diuretic, helps reduce excessive sodium and fluid in the body to further aid in lowering blood pressure. This combination is an effective alternative when blood pressure is not controlled with mono-treatment. Therefore, this medication is used to improve blood pressure control in essential hypertension.

How to take

Adult dose

Before administering this medicine, it is recommended that the dose of olmesartan medoxomil or hydrochlorothiazide be adjusted individually. If blood pressure is not adequately controlled with the individual components, administer 1 tablet of this medicine once daily, regardless of meals. Adjust the dose at intervals of 2~4 weeks, taking the patient's blood pressure response into consideration. A marked reduction in blood pressure may occur when olmesartan medoxomil is added to treatment in patients taking high-dose hydrochlorothiazide monotherapy or when such patients are switched to this medicine (olmesartan medoxomil/hydrochlorothiazide), as well as in patients with volume depletion or hyponatremia. In these cases, reduce the hydrochlorothiazide dose to 12.5mg before adding olmesartan medoxomil. <Elderly patients> In elderly patients, start with the lowest dose and use caution when adjusting the dose, taking into consideration the patient's renal or cardiac function, comorbidities, and other concomitant medications. <Patients with renal impairment> This medicine (olmesartan medoxomil/hydrochlorothiazide) is generally administered to patients with mild or moderate renal impairment (creatinine clearance>30mL/min). Do not administer this medicine (olmesartan medoxomil/hydrochlorothiazide) to patients with more severe renal impairment, as loop diuretics are preferable to thiazide diuretics in these patients. <Patients with hepatic impairment> Use of this medicine is not recommended in patients with hepatic impairment because there is no experience with its use in these patients.

Child dose

The safety and efficacy in children have not been established.

Precautions

This medication can cause serious harm or death to the fetus and newborn if taken during the second or third trimester of pregnancy. Hence, it should be discontinued immediately upon confirmation of pregnancy. Do not take if you are allergic to any of the components or have specific kidney or liver diseases. Patients with low blood pressure or insufficient salt and blood volume should carefully evaluate their condition before use and take appropriate measures if necessary. This medication may affect kidney function; therefore, patients with kidney disease should regularly monitor kidney function and electrolyte levels through blood tests. Patients with liver diseases or specific heart conditions need special precautions when taking this medication. This medication can cause skin sensitivity or photosensitivity reactions, so exposure to sunlight should be cautious, and regular skin checks are recommended as it may increase the risk of skin cancer. While taking this medication, side effects such as dizziness, headache, dyspepsia, and blood pressure changes may occur, and if symptoms are severe, consultation with a physician is necessary. Care should be taken when taking potassium supplements or potassium-sparing diuretics as blood potassium levels may fluctuate. Drug interactions may occur when taken with other antihypertensives, certain pain relievers, lithium, or specific antibiotics; thus, it is essential to inform your doctor or pharmacist. This medication is not recommended for breastfeeding women. If you are breastfeeding, you should discontinue either the medication or breastfeeding. Safety in the elderly and children has not been adequately established, so consult a physician when taking. In case of overdose, symptoms such as low blood pressure, electrolyte imbalances, and dehydration may occur, so immediate medical attention is required. This medication has a strong effect on lowering blood pressure; thus, care should be taken as dizziness may occur while driving or operating machinery.

Side effects

Nausea, Hyperuricemia, Dizziness, Upper Respiratory Tract Infection, Headache, Urinary Tract Infection, Chest Pain, Back Pain, Peripheral Edema, Vertigo, Abdominal Pain, Dyspepsia, Gastroenteritis, Diarrhea, Elevated AST, Elevated GGT, Elevated ALT, Hyperlipidemia, Increased Creatine Phosphokinase, Hyperglycemia, Arthritis, Arthralgia, Myalgia, Cough, Rash, Hematuria, Facial Edema, Weakness, Angioedema, Anaphylactic Reaction, Vomiting, Rhabdomyolysis, Acute Renal Failure, Increased Serum Creatinine, Hair Loss, Itching, Urticaria, Palpitations, Fatigue, Drowsiness, Emotional Blunting, Restlessness, Interstitial Pneumonia, Pulmonary Edema, Acute Respiratory Distress Syndrome, Orthostatic Hypotension, Arrhythmia, Temporary Visual Disturbance, Jaundice, Choroidal Exudate, Jaundice, Hepatitis, Acute Cholecystitis, Necrotizing Vasculitis, Interstitial Pneumonia, Facial Flushing, Photosensitivity, Weakness, Stevens-Johnson Syndrome, Erythema Multiforme, Exfoliative Dermatitis, Toxic Epidermal Necrolysis, Chronic Malabsorption Syndrome, Intestinal Vascular Edema, Chronic Malabsorption Syndrome - Like Intestinal Disease, Intestinal Vascular Edema, Elevated Blood Pressure, Epistaxis, Asthma, Thrombocytopenia, Leukopenia, Aplastic Anemia, Hemolytic Anemia, Purpura, Anorexia, Polydipsia, Abdominal Discomfort, Constipation, Abdominal Pain, Pancreatitis, Jaundice (Intrahepatic Cholestatic Jaundice), Sialadenitis, Xerostomia, Abnormal Liver Function Tests, Autoimmune Hepatitis, Exacerbation of Systemic Lupus Erythematosus, Parathyroid Disorder, Muscle Cramps, Sensory Disturbances, Angioedema, Anaphylactic Reaction, Chronic Malabsorption Syndrome (Sprue) - Like Intestinal Disease, Intestinal Vascular Edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or humidity, so it is important to store it in a sealed container. The storage temperature should maintain room temperature between 1 to 25 degrees Celsius while avoiding direct sunlight and keeping it in a cool place.

Appearance and packaging

Appearance

Round film-coated tablet with a reddish-yellow color

Package unit

30 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.